22157.jpg
China Pioneers Innovative Drug Development with a Surge in CAR-T Cell and ADC Therapy Advancements
20. Dezember 2024 09:26 ET | Research and Markets
Dublin, Dec. 20, 2024 (GLOBE NEWSWIRE) -- The "Drug Development Trends in China" report has been added to ResearchAndMarkets.com's offering.China has emerged as a critical player in global drug...
22157.jpg
FDA (Food and Drug Administration) Drug Approval Process Training Course: Comprehensive Programme Covering Procedures for Submission of INDs, NDAs, ANDAs and 505(b)(2) (LIVE ONLINE EVENT/ON-DEMAND)
21. November 2024 06:08 ET | Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
22157.jpg
Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union: 2-Day Online Training Course (October 3-4, 2024)
03. Juli 2024 11:18 ET | Research and Markets
Dublin, July 03, 2024 (GLOBE NEWSWIRE) -- The "Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union Training Course" conference has been added to ResearchAndMarkets.com's offering. ...
FDA Approval of ELEVIDYS for Duchenne Muscular Dystrophy Patients Ages 4 and Above
Muscular Dystrophy Association Applauds Expanded US FDA Approval of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy Patients Ages 4 and Above
20. Juni 2024 18:42 ET | Muscular Dystrophy Association
New York, June 20, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the U.S. Food and Drug Administration’s expanded approval of ELEVIDYS (delandistrogene...
22157.jpg
Russia and the Eurasian Union Pharmaceutical Regulatory Affairs Training Course (ONLINE EVENT: June 24-27, 2024/On-Demand)
18. Juni 2024 11:02 ET | Research and Markets
Dublin, June 18, 2024 (GLOBE NEWSWIRE) -- The "Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union Training Course" conference has been added to ResearchAndMarkets.com's offering. ...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
30. Mai 2024 13:41 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
New FDA Drug Approval for Duchenne Muscular Dystrophy
Muscular Dystrophy Association’s Funding of Foundational Research Leads to New FDA Approved Treatment Duvyzat (givinostat) for Duchenne Muscular Dystrophy
21. März 2024 19:45 ET | Muscular Dystrophy Association
New York, March 21, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association’s funding of foundational research leads to new drug approval by the US Food and Drug Administration (FDA) of Duvyzat...
22157.jpg
The FDA (Food and Drug Administration) Drug Approval Process, 2 Day Virtual Training Course
22. Januar 2024 11:43 ET | Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" has been added to ResearchAndMarkets.com's offering. The US is the...
22157.jpg
Mastering the FDA Drug Approval Process: Strategies for Success in the US Pharmaceutical Market (February 6-7, 2024)
02. November 2023 07:28 ET | Research and Markets
Dublin, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
New FDA Drug Approval for Duchenne Muscular Dystrophy
Muscular Dystrophy Association-Supported Drug AGAMREE® (vamorolone) Approved for the Treatment of Duchenne Muscular Dystrophy by the FDA
26. Oktober 2023 16:24 ET | Muscular Dystrophy Association
New York, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of AGAMREE® (vamorolone), a structurally unique...